10th May 2018 | Pope Woodhead

This webinar outlines how providing secure and validated systems can help pharmaceutical companies mitigate risk and enhance visibility across their business critical functions.

Benefits of such systems include:
• Web based platform founded on state of the art business process and document management functionality
• Compliant, auditable and global ‘one stop’ systems to track a range of vital Safety and Risk Management activities
• Active notification of the ‘right’ information to users based on their needs
• Dynamic dashboards that enable you to see the status of any item with just a couple of clicks

Read more ...

28 March 2018 | Pope Woodhead, UK

In an environment of constrained budgets, the onus lies on manufacturers to provide evidence about the burden of a disease and the future promise of their therapy. Tools such as predictive models can help bridge the existing data and future outcomes which can have many benefits, such as improved understanding of the long term impact of a disease and enhanced knowledge of key morbidities and their impact on mortality

Read more ...

3 November 2017 | Pope Woodhead, UK

Moving from Promise to Reality

In this webinar we illustrated the trends and challenges within pharma and the importance/potential they will bring to reality within industry. Moving from volume to value is a mantra now frequently heard in the US. The move to outcomes or performance based health delivery measures for ACOs and IDNs has helped pave the way for a new wave of performance based contracts between pharma and payers in the US.

Read more ...

30 November 2017 | Pope Woodhead, UK

Structured benefit-risk assessment became a high priority with adoption of ICH M4E(R2), which provided a new format for benefit-risk conclusions within regulatory submissions. The guideline has been widely implemented this year, including by EMA in January and FDA in July.

This webinar led by Dr Steve Mayall, a Principal Consultant and expert in the benefit-risk area, provided an update on key aspects of benefit-risk assessment in today’s environment, highlighting practical experiences and challenges.

Read more ...

13 July 2017 - Pope Woodhead, UK

Over the last few years there has been a significant investment in to a pipeline of cell and gene therapy products across oncology as well as in rare diseases and diseases with high unmet needs. While the pipeline of products offer the promise of transforming treatment and outcomes for patients, there are certain environmental and product related barriers to access and/or utilisation.

Read more ...

Contact Us

Please fill out the form below to request more information on an Event/Webinar. Alternatively email